Novo Nordisk reported DKK225.16B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Bausch Health Companies USD 4.54B 14M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pacira USD 122.01M 13.22M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026